Navigation Links
Engineered immune cells produce complete response in child with an aggressive pediatric leukemia
Date:12/9/2012

By reprogramming a 7-year-old girl's own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom-designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child's doctors found that she had no evidence of cancer.

Pediatric oncologist Stephan A. Grupp, M.D., Ph.D., of The Children's Hospital of Philadelphia, and colleagues from the University of Pennsylvania presented updated results of the clinical trial involving these engineered cells at the American Society of Hematology (ASH) annual meeting today in Atlanta. Grupp is the director of Translational Research for the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia, and a professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania.

Grupp's research builds on his ongoing collaboration with Penn scientists who originally developed the modified T cells as a treatment for B-cell leukemias. The Penn team reported on early results of a trial using this cell therapy in adult chronic lymphocytic leukemia (CLL) patients in August of 2011. Carl H. June, M.D., of the Perelman School of Medicine at the University of Pennsylvania, leads this research group, which along with Grupp's work, is presenting new data at the ASH meeting showing that nine of 12 patients with advanced leukemias in the clinical trial, including two children, responded to treatment with CTL019 cells.

One of the nine responding patients is the 7-year-old with acute lymphoblastic leukemia (ALL). Grupp and Penn colleagues adapted the treatment to combat ALL, the most common childhood leukemia, and also the most common childhood cancer. Although physicians can cure roughly 85 percent of ALL cases, the
'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-970-3685
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Leukemia patients remain in remission more than 2 years after engineered T cell therapy
2. Bioengineered marine algae expands environments where biofuels can be produced
3. Soft Robotics: A groundbreaking new journal on engineered soft devices that Interact with Living Systems
4. Engineered bacteria can make the ultimate sacrifice
5. Ecologist: Genetically engineered algae for biofuel pose potential risks that should be studied
6. Success of engineered tissue depends on where its grown
7. Lab-engineered kidney project reaches early milestone
8. Engineered robot interacts with live fish
9. Engineered microvessels provide a 3-D test bed for human diseases
10. New research reveals challenges in genetically engineered crop regulatory process
11. Ultrasound idea: Prototype NIST/CU bioreactor evaluates engineered tissue while creating it
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/12/2015)... N.C. , March 12, 2015 The ... at Brenner Children,s Hospital, part of Wake Forest Baptist ... outreach initiative for the 2015 ACC Men,s Basketball Tournament. ... pictures with them and getting their autographs. ... Forest Baptist. It is the only children,s hospital in ...
(Date:3/11/2015)... 2015   The Sync Project™ today ... measure and harness music to improve health. The ... objective measurements of physiology, enabling the study of ... large populations. It is designed for medical and ... rigorous studies and accelerate the discovery of the ...
(Date:3/10/2015)... , March 10, 2015  NXT-ID, Inc. (NASDAQ: ... the "Company"), a biometric authentication company focused on ... Wocket™ smart wallet has been named the "Number ... Modern. Rethink Modern ( http://www.rethinkmodern.com/ ) ... for your home and lifestyle that have a unique ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... fractures due to osteoporosis are a major cause of disability ... are patients who have already suffered one fragility fracture; they ... compared to others who have not fractured. Nevertheless ... and treat these patients, leaving them exposed to debilitating and ...
... 2013 Reportlinker.com announces that a new ... catalogue: India Biometrics Market ... http://www.reportlinker.com/p01162444/India-Biometrics-Market-Forecast-and-Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems The biometric security ... India . With the ...
... LLC are pleased to announce a new license ... the unique characteristics of CSIRO,s Reversible Addition-Fragmentation chain ... high-end polymer development capabilities for the biotech industry., ... Hayes said the agreement would allow the company ...
Cached Biology News:New review sets international standards for best practice in fracture liaison services 2India Biometrics Market Forecast and Opportunities, 2018 2India Biometrics Market Forecast and Opportunities, 2018 3India Biometrics Market Forecast and Opportunities, 2018 4India Biometrics Market Forecast and Opportunities, 2018 5India Biometrics Market Forecast and Opportunities, 2018 6
(Date:3/27/2015)... , March 27, 2015 Working in ... Hospital in London , Richmond Pharmacology is ... global Phase 3 study for an investigational RNAi therapeutic being ... disease affecting the nerves and heart. Read ... Based at St Georges University of ...
(Date:3/26/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... solutions for the detection of foodborne pathogens, today ... and full year ended December 31, 2014. ... quarter ended December 31, 2014 was $1.4 million ... 2013 and $1.5 million for the third quarter ...
(Date:3/26/2015)... , March 26, 2015  BioNano Genomics, Inc., ... of  Terry Salyer as chief commercial officer. Salyer ... effective, worldwide sales teams in life sciences. At BioNano, ... System, a genome-mapping platform to assemble a comprehensive ... structural variations. To date, 32 institutions located in ...
(Date:3/26/2015)... Texas (PRWEB) March 26, 2015 ReliantHeart, ... technologies, and Transonic, a supplier of precision transit-time flow ... that will greatly improve the efficiency of the ... enable LVAD patients to experience greater mobility and peace ... with the miniature flow board, will draw 1/6th of ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... 30 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... leading plasma-based pharmaceutical companies in the,People,s Republic of ... approval from the Guangxi Province Bureau of Health, ... Pu Bei County, Guangxi Province., The new ...
... PITTSBURGH, June 30 Cellumen, Inc., the Cellular,Systems ... research,collaboration with the National Center for Toxicology Research ... Administration (FDA). Under the,agreement, Cellumen will use its ... samples of known liver toxicity,compounds including both failed ...
... 30 Cardiac Science,Corporation (Nasdaq: CSCX ), ... and informatics products, announced today,that it has been ... Company,s,addition to the Russell 3000 Index was made ... Selection to the Russell 3000 index means Cardiac,Science ...
Cached Biology Technology:China Biologic Products Announces Approval for Setting Up a New Plasma Collection Station in Pu Bei County, Guangxi Province 2China Biologic Products Announces Approval for Setting Up a New Plasma Collection Station in Pu Bei County, Guangxi Province 3Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology 2Cardiac Science Announces Inclusion in Russell 3000 Index 2
... is designed to allow ampicillin selection in ... driving the gene for ampicillin resistance is ... promoter. It mediates higher transcription efficiency than ... polyadenylation signal terminates the ampicillin expression. The ...
... for the fast and simple integration of ... position (for the generation of transgenic mouse ... to allow neomycin / kanamycin selection in ... prokaryotic promoter (gb2) for expression of kanamycin ...
... cassette is designed to allow chloramphenicol ... prokaryotic promoter gb2 driving the gene ... modified version of the Em7 promoter. ... the generally used Tn5 promoter. A ...
... AMPure is a magnetic bead-based ... no sample transfer, centrifugation or ... small and large PCR extension ... microplates. Agencourt AMPure can easily ...
Biology Products: